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Abstract
The Glucose-Insulin-Glucagon nonlinear model [1–4] accurately describes how the body
responds to exogenously supplied insulin and glucagon in patients affected by Type I diabetes.
Based on this model, we design infusion rates of either insulin (monotherapy) or insulin and
glucagon (dual therapy) that can optimally maintain the blood glucose level within desired limits
after consumption of a meal and prevent the onset of both hypoglycemia and hyperglycemia.
This problem is formulated as a nonlinear optimal control problem, which we solve using the
numerical optimal control package PSOPT . Interestingly, in the case of monotherapy, we find
the optimal solution is close to the standard method of insulin based glucose regulation, which is
to assume a variable amount of insulin half an hour before each meal. We also find that the
optimal dual therapy (that uses both insulin and glucagon) is better able to regulate glucose as
compared to using insulin alone. We also propose an ad-hoc rule for both the dosage and the
time of delivery of insulin and glucagon.
1 Introduction
Insulin and glucagon are pancreatic hormones that help regulate the levels of glucose in the
blood. Insulin is produced by the beta-cells in the pancreas and carries glucose from the
bloodstream to the cells throughout the body. Glucagon releases glucose from the liver into the
bloodstream in order to prevent hypoglycemia. In people affected by diabetes insulin is either
absent (type I diabetes) or not produced in the proper amount (type II diabetes). In type I
diabetes the body’s immune system attacks and destroys the beta cells. As a result, insulin is not
produced and glucose accumulates in the blood which may cause serious harm to several organs.
Type II diabetes is a metabolic disorder in which the beta cells are unable to properly regulate
the blood glucose within limits. Common therapies for diabetes involve the administration of
exogenous insulin. Currently glucagon is not typically included in therapies because it does not
preserve its chemical properties at room temperature and also because diabetic patients are still
able to produce it.
The control of glucose levels in diabetic patients is an active field of research [5–19]. The
approval by the FDA of a simulator which replaces in-vivo with in-silico therapy testing has
greatly benefited this area of research. This simulator implements a mathematical model, first
proposed in [1] and updated in [2–4], and provides an alternative to often slow, dangerous and
expensive human testing.
Typically, insulin is administered manually approximately half an hour before each meal
where the amount is determined from the current glucose level (measured through a blood sugar
test), the expected glucose intake, and the patient’s sensitivity to insulin. In what follows we will
refer to this as the standard therapy. In 1992 the first insulin pumps were introduced to the
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market. They delivered both a consistent basal amount of insulin and an insulin bolus determined
by the patients based on their glucose level. It was only in 2016 that the first autonomous system
for glycemic control was approved by the FDA. The system consists of an insulin pump, a
sensor that measures the blood glucose level continuously in time, and control software that is
able to regulate the insulin level in the blood without needing any input from the patient.
Many control techniques have been proposed and tested to regulate blood glucose levels
using insulin pumps including PID (proportional–integral–derivative) control [5, 6, 8–10, 20],
fuzzy logic control [11–13] and bio-inspired techniques [14] which do not rely on a
mathematical model. In [21] closed loop control has been used on a so called “minimal
model” [22–24]. In [15–18, 25] a linear model predictive control (MPC) has been used in a
model with fixed structure but for which parameters are constantly updated to adapt to the
patient’s response. In [26] linear MPC has been used in silico. In [27] MPC has been applied to
a system linearized around the operating points of a physically derived nonlinear model and
in [28] multiple model probabilistic predictive control has been used. In [29] MPC has been
applied together with a moving horizon estimation technique to a linear model. Most of the
models used when designing the above controllers are simplified versions of the FDA approved
model and all the control techniques considered only use insulin (but not glucagon) as control
input.
Because insulin delivered exogenously is not subject to normal physiological feedback
regulation, hypoglycemia is common in patients with Type 1 diabetes who undergo
treatment [30]. For these patients it has been proposed that exogenous insulin can be used to
lower their blood glucose level and exogenous glucagon can be used to prevent
hypoglycemia [31, 32]. Currently, a commercial pump that delivers both insulin and glucagon is
not available, and the development of a two-drug artificial pancreas is still the subject of clinical
research [33–41]. An outstanding research question, which we address in this paper, is the
determination of the temporal dosages of both insulin and glucagon, in the case of the dual
therapy.
Following the study in [42] which optimized multi-drug therapies for autophagy regulation,
here we seek to determine an optimal strategy for delivery of both insulin and glucagon. We
consider the combined effects of insulin and glucagon in regulating blood glucose levels in
patients with Type 1 diabetes, using the model in [3] and nonlinear optimal control theory.
Additionally, the objective function that we seek to minimize is the Blood Glucose Index which
is a well known tool to measure the risk for a patient to enter either hyperglycemia or
hypoglycemia. To design the optimal control problem, we use the balance control technique of
ref. [43], which introduces a trade-off between the error allowed with respect to a state based
cost (Blood Glucose Index) and the control effort. Our goal is to evaluate the performance limits
of a control algorithm in the blood glucose problem, and to discuss the advantages of the dual
drug therapy compared to the single drug therapy. Note that even though we do not attempt to
design a closed-loop control strategy that works without the patient’s intervention, the solution
we propose can be adapted for that purpose.
From solving the optimal control problem for a family of objective functions derived from
the balance control paradigm, we observe the emergence of a pattern, from which we propose a
simple rule for the delivery of insulin and glucagon similar to the standard therapy, but for the
case that both insulin and glucagon are used. While this therapy is suboptimal, we see that it still
performs better than the optimal solution with insulin alone.
Finally, we test the robustness of the optimal solution. While optimal control does not
guarantee robustness of the optimal solution with respect to model uncertainty or parameter
mismatches, we see that our proposed solution still performs well in the presence of model
parameter perturbations and variations affecting the time and glucose intake of the meal.
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2 Materials and methods
2.1 Model and Parameters
We consider the model in [3, 4] which is a system of nonlinear ordinary differential equations
(ODEs). The equations are given in Eqs. (S1)-(S9) in supplementary information section S1. We
write the ODEs in Eqs. (S1)-(S9) in the form
x˙(t) = f(x(t),u(t), D(t),Θ)
G(t) = x1/VG
(1)
where the state vector is x = [x1(t), x2(t), ..., x17(t)]T and t is the physical time (in min). In
Table 1 we tabulate all of the variables xi and their names. The control input vector is
u(t) = [uI(t), uG(t)]T , where uI(t) ≥ 0 is the exogenous insulin infusion rate (in insulin
Unit/min) and uG(t) ≥ 0 is the exogenous glucagon infusion rate (mg/min). Both uI(t) and
uG(t) are the external inputs to the system in Eq. (1). The scalar quantity D(t) represents the
exogenous glucose input, that is, the glucose intake with a meal. The output of the system is the
quantity G(t), which measures the density of glucose in the blood, obtained as the ratio between
the plasma glucose and the distribution volume of glucose VG.
When uI(t) = 0, uG(t) = 0 and D(t) = 0, the model reaches (for physically meaningful
parameters) a steady state, also known as the basal condition of a patient. The basal condition
depends upon the parameters of the models Θ. We denote by ΘGb a set of parameters for which
the basal glucose level G is equal to Gb. The basal levels for the other states are found according
to Eqs. (S11).
Table 1. Variables and their physical meaning
Variables Names Representing Units
x1 Gp Mass of glucose in plasma mg/kg
x2 Gt Mass of glucose in tissue mg/kg
x3 Il Mass of insulin in liver pmol/kg
x4 Ip Mass of insulin in plasma pmol/kg
x5 I
′ Mass of delayed in compartment 1 pmol/L
x6 X
L Amount of delayed insulin action on EGP (Endogenous glucose production) pmol/L
x7 Qsto1 Amount of solid glucose in stomach mg
x8 Qsto2 Amount of liquid glucose in stomach mg
x9 Qgut Amount of glucose in intestine mg
x10 X Amount of interstitial fluid pmol/L
x11 SR
s
H Amount of static glucagon ng/L/min
x12 H Amount plasma glucagon ng/L
x13 X
H Amount of delayed glucagon action on EGP ng/L
x14 Isc1 Amount of nonmonomeric insulin in the subcutaneous space pmol/kg
x15 Isc2 Amount of monomeric insulin pmol/kg
x16 Hsc1 Amount of glucagon in the subcutaneous space 1 ng/L
x17 Hsc2 Amount of glucagon in the subcutaneous space 2 ng/L
State variables and their physical meaning.
2.2 Problem Formulation
We formulate a nonlinear optimal control problem with two control goals. The first goal is to
regulate the glucose at levels corresponding to low clinical risk of either hyperglycemia or
February 28, 2019 3/29
hypoglycemia during a time period over which a meal is consumed. We assume that a meal is
ingested at time t = τD, which we assume to be modeled as a Dirac delta function
D(t) = Dδ(t− τD). To evaluate the clinical risk of a particular glycemic value, Kovatchev et
al. [44, 45] proposed the Blood Glucose Index (BGI), defined as
BGI (G(t)) = 10
(
1.509
(
(lnG(t))1.084 − 5.3811))2 ,
where a small BGI value corresponds to low risk of either hyperglycemia or hypoglycemia. This
metric also takes into account the fact that (i) the target blood glucose range as defined by the
Diabetes Control and Complications Trial [46] (between 70 and 180 mg/dL) is not symmetric
about the center of the range and (ii) hypoglycemia occurs at glucose levels closer to the basal
level than hyperglycemia. The second goal is to limit the overall usage of insulin and/or
glucagon over the period [t0, tf ].
We formulate the optimization problem according to these two goals,
min
u(t)
J =
∫ tf
t0
[αpBGI (G(t)) + αIu
p
I(t) + αGu
p
G(t)] dt, (2)
subject to the following constraints,
x˙(t) = f(x(t),u(t), Dδ(t− τD),ΘGb), u(t) = [uI(t) uG(t)]T (3a)
GL < G(t) < GU (3b)
uLI ≤ uI(t) ≤ uUI (3c)
0 ≤ uG(t) ≤ uUG (3d)
0 ≤ ∫ tf
t0
uI(t)dt ≤ φUI (3e)
0 ≤ ∫ tf
t0
uG(t)dt ≤ φUG (3f)
x(t0) = x¯ (3g)
In Eqs. (2) and (3), the insulin infusion rate uI(t) and the glucagon infusion rate uG(t) are the
two control inputs. The three coefficients αp, αI and αG in Eq. (2) are tunable factors through
which we may vary the weight associated with each of the three terms in the cost function J .
The first coefficient, αp is dimensionless while the units of αI and αG are (U/min)−p and
(mg/min)−p, respectively. Note that by setting uG = 0 in Eq. (3d), we have an optimal control
problem in terms of insulin only.
The first term in the objective function (2) defines a regulation problem, i.e., we try to
maintain the glucose at low risk levels. The second and third terms in the cost function are
chosen to avoid using excess insulin or glucagon. For p = 1 in Eq. (2), the second and third
terms define a ‘minimum fuel’ problem, thus we call the optimization problem ReMF
(Regulation and Minimum Fuel). In this case, we expect the optimal solution to consist of
pulsatile inputs u∗I(t) and u
∗
G(t) [47, 48]. For p = 2, the second and third term inside the cost
function define a ‘minimum energy’ problem, thus we call the optimization problem ReME
(Regulation and Minimum Energy). In this case, we expect the optimal control inputs u∗I(t) and
u∗G(t) to be continuous. The set of equations in (3a) coincide with the ODEs in Eqs. (S1)-(S9)of
the supplemental information. In Eq. (3b) GL and GU are the lower and upper bounds for G(t),
they can be set in order to avoid undesired hypoglycemic or hyperglycemic states. In Eqs. (3c)
and (3d) uUI and u
U
G are upper bounds for the insulin and glucagon delivery rates, respectively.
These constraints are set by the maximum infusion rates allowed by the insulin pump. In Eq. (3c)
uLI ≥ 0 is the lower bound for uI(t), i.e., a minimum insulin delivery rate that can be used to set
a basal insulin infusion rate to counteract endogenous glucose production [49]. Finally, in Eqs.
(3e, 3f), φUI and φ
U
G set limits to the total limits of insulin and glucagon that can be delivered
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over the time period [t0, tf ]. The initial condition x¯ in Eq. (3g) defines the patient’s condition
before administration of the therapy. In the Results section, we discuss how we choose the
bounds on G(t), uI(t), uG(t), φI , φG, the control time period [t0, tf ] and the initial condition x¯.
Our goal is to find an optimal solution which satisfies the constraints in Eq. (3) and
minimizes the objective function (2). Note that the BGI only depends upon G(t): we are making
no attempt to control the states of the system, only its output. In the literature, such an approach
is often referred to as target control [47, 50].
2.3 Method: Pseudo-Spectral Optimal Control
Optimal control theory combines aspects of dynamical systems, optimization, and the calculus
of variations [47] to solve the problem of finding a control law for a given dynamical system
such that the prescribed optimality criteria are achieved. The equations (2) and (3) together form
a constrained optimal control problem, which can generally be written as,
min
u(t)
J(x(t),u(t), t) =
∫ tf
t0
F (x(t),u(t), t) dt
s.t. x˙(t) = f(x(t),u(t), t)
eL ≤ e(x(t0), x(tf ), t0, tf ) ≤ eU
hL ≤ h(x(t),u(t), t) ≤ hU
t ∈ [t0, tf ]
(4)
In general, there exists no analytic framework that is able to provide the optimal time traces of
the controls u∗(t) and the states x∗(t) in (4), and so we must resort to numerical techniques.
Pseudo-Spectral Optimal Control (PSOC) is a computational method for solving optimal
control problems. Here we present a brief overview of the theory of pseudo-spectral optimal
control. PSOC has become a popular tool in recent years [51, 52] that has let scientists and
engineers solve optimal control problems like (4) reliably and efficiently in applications such as
guiding autonomous vehicles and maneuvering the international space station [52]. PSOC is an
approach by which an OCP can be discretized by approximating the integrals by quadratures and
the time-varying states and control inputs with interpolating polynomials. Here we summarize
the main concept of the PSOC. We choose a set of N discrete times {τi} i = 0, 1, . . . , N where
τ0 = −1 and τN = 1 with a mapping between t ∈ [t0, tf ] and τ ∈ [−1, 1]. The times {τi} are
chosen as the roots of an (N + 1)th order orthogonal polynomial such as Legendre polynomials
or Chebyshev polynomials. The choice of dicretization scheme is important to the convergence
of the full discretized problem. For instance, if we choose the roots of a Legendre polynomial as
the discretization scheme, the associated quadrature weights can be found in the typical way for
Gauss quadrature. The time-varying states and control inputs are found by approximating them
with Lagrange interpolating polynomials,
xˆ(τ) =
N∑
i=0
xˆiLi(τ) (5a)
uˆ(τ) =
N∑
i=0
uˆiLi(τ), (5b)
where xˆ(τ) and uˆ(τ) are the approximations of x(τ) and u(τ), respectively, and Li(τ) is the ith
Lagrange interpolating polynomial. The dynamical system is approximated by differentiating
the approximation xˆ(τ) =
∑N
i=0 xˆiLi(τ) with respect to time.
dxˆ
dτ
=
N∑
i=0
xˆi
dLi
dτ
(6)
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Let Dk,i = ddτLi(τk) which allows one to rewrite the original dynamical system constraints in
(4) as the following set of algebraic constraints.
N∑
i=0
Dk,ixi − tf − t0
2
f(xˆi, uˆi, τi) = 0, k = 1, . . . , N (7)
The integral in the cost function is approximated as,
J =
∫ tf
t0
F (x,u, t) ≈ Jˆ = tf − t0
2
N∑
k=1
F (xˆk, uˆk, τk) (8)
The original time-varying states, control inputs, the dynamical equations constrained and the
cost function are now discretized approximation of the continuous NLP problem. Thus the
discretized approximation of the original OCP is compiled into the following nonlinear
programming (NLP) problem.
min
ui
i=0,...,N
Jˆ =
tf − t0
2
N∑
i=0
wif(xˆi, uˆi, τi)
s.t.
N∑
i=0
Dk,ixˆi − tf − t0
2
f(xˆk, uˆk, τk) = 0, k = 0, . . . , N
eL ≤ e(xˆ0, xˆN , τ0, τN ) ≤ eU
hL ≤ h(xˆk, uˆk, τk) ≤ hU , k = 0, . . . , N
ti =
tf − t0
2
τi +
tf + t0
2
(9)
We have used PSOPT [53], an open-source PSOC library, to perform the above PSOC
discretization procedure. The NLP in (9) can be solved with a number of different techniques,
but here we use an interior point algorithm [54] as implemented in the open-source software
Ipopt [55].
2.3.1 Continuous Approximation of Non-differential Function in ODEs
The optimization algorithms implemented in PSOPT require the derivatives of the function
f(x(t),u(t),ΘGb) exists. As there are terms that contain discontinuities in Eqs. (S1)-(S9), we
replace them with smooth approximations which are described in section S3 of the SI.
3 Results
We now describe in more detail the optimal control problem in Eqs. 2 and 3 by setting the
constraint and parameter values. In Fig. 1A we plot the function BGI(G) versus the glucose G.
The minimum BGI (G) occurs at G = Gd = 112.51 mg/dL, which corresponds to a clinical
target set for the glucose level [46]. Based on the data in [56], the average fasting plasma glucose
level of patients with type I diabetes is Gb = 130 (mg/dL). Thus, we set the the basal glucose
level Gb = 130 (mg/dL). The parameters ΘGb are set so that the steady state glucose is 130
(mg/dL) in the absence of a meal and of exogenously supplied insulin, i.e., we compute Θ130.
We set the upper and lower bounds for the glucose level, GL and GU in Eq. (3b), to satisfy
the target blood glucose range, 90 ≤ G(t) ≤ 180 [46]. The control time period is
[t0, tf ] = [0, 300] minutes, and we assume that a meal with 70 grams of glucose is consumed at
time t = 60 min (i.e., D(t) = 70δ(t− 60)).
We consider a situation in which the patient’s glucose level is partially controlled by
providing a constant but low insulin infusion rate ub > 0 (which is common for patients who use
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Fig 1. A) The Blood Glucose Index (BGI(G(t))) as a function of the blood glucose G(t). The function
is minimized at G(t) = Gd = 112.51 (mg/dL). B) The response of glucose (G(t)) to different
time-constant basal insulin infusion rates in the absence of a meal. We see that as ub increases, the
glucose is further down regulated.
an insulin pump) [49] and serves to compensate for the endogenous glucose production. In
figure 1B we show glucose response G(t) for different values of constant ub in the absence of a
meal. We observe that for ub = 0.0024 (U/min), G(t) converges to the desired glucose level Gd.
We thus set the lower bound of uI(t) in Eq. (3c), uLI = ub, while its upper bound is set to
uUI = 15 (in U/min), the maximum insulin flow allowed in commercial pumps [57]. In the
absence of commercially available glucagon pumps, we will assume that a pump mechanically
similar to an insulin pump is used to deliver glucagon. Since the maximum flow rate for an
insulin pump is 0.15 mL/min (1 mL of insulin solution contains 100 U of insulin), and normally
1 mg of glucagon is diluted in 1 mL of solution, the maximum glucagon flow rate in Eq. (3d) is
set to uUG = 0.15 mg/min.
The amount of insulin administered in a bolus to a patient with a basal glucose level lower
than 150 mg/dL normally ranges between 0.12 and 0.2 U/kg [58]. As the body mass of the
in-silico patient we consider is 78 kg, we set φUI = 16 U in Eq. (3e). The maximum total
amount of glucagon administered in one shot to a patient who is in a hypoglycemic state is 1 mg,
and a second identical shot can be administered after thirty minutes. We thus choose the
maximum total amount of glucagon used (as defined in Eq. (3f)) throughout the five hour
therapy to be φUG = 1mg.
The choice of the initial condition x¯ in Eq. (3g) is critical. We select the initial condition so
that the solution of our optimal control problem only attempts to regulate glucose in response to
a meal. In the results presented we have set the initial condition equal to the values of the states
when uI(t) = ub after a period of fasting (the final point of the blue curve in Fig. 1B). If we
were to select any alternative initial condition then the solution to the optimal control problem
would try to ‘correct’ the initial condition as well, making comparisons between solutions
difficult.
Once the parameters, bounds, the control time period and the initial condition are set, we
solve the nonlinear optimal control problem using PSOPT . We first solve the optimal control
problem without glucagon (i.e., uUG = 0), and then we solve the optimal control problem using
both insulin and glucagon.
To evaluate the effectiveness of the obtained results, we introduce the following measures.
• The cumulative insulin rI(t) and cumulative glucagon rG(t) used up to time t,
rI(t) =
∫ t
t0
uI(τ)dτ, rG(t) =
∫ t
t0
uG(τ)dτ.
• The total amount of insulin φI = rI(tf ) and the total amount of glucagon φG = rG(tf )
used up to final time tf .
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• The integral of BGI over the entire time period [t0, tf ],
∆ =
∫ tf
t0
BGI(G(t))dt.
where a large ∆ indicates that the patient is at higher risk of either hyperglycemia or
hypoglycemia for a prolonged period of time.
• The maximum and minimum values attained by the blood glucose level over the entire
time period [t0, tf ],
Gmax = max
t∈[t0,tf ]
G(t), Gmin = min
t∈[t0,tf ]
G(t),
which measure the risk for either hyperglicemia or an hypoglicemia [45, 59], respectively.
3.1 Insulin as Control Input
In this section we use only insulin as control input, i.e., we set uG = 0 in Eq. (3a). As the orders
of magnitude of the terms BGI and upI in the objective function are different, it is important to
find the appropriate values of the scaling factors αp and αI . In what follows, we use a
Pareto-front analysis to determine these values. We first rewrite the objective function as
J =
∫ tf
t0
[εBGI(G(t)) + upI ] dt (10)
where ε = αp/αI . In Figs. 2(A–D) we plot ∆, Gmin, Gmax and φI as functions of the
coefficient ε. By looking at these plots, we see that the four measures can be divided into two
groups. On the one hand, ∆ and Gmax (panels A and C), improve (decrease) as ε increases, with
a sharp transition around ε = 10 for the ReMF problem and around ε = 103 for the ReME
problem. On the other hand, Gmin and φI (panels B and D), behave in the opposite way,
i.e., they improve (insulin decreases and the minimum glucose level increases) as ε decreases,
again with a sharp transition around ε = 10 for the ReMF problem and around ε = 103 for the
ReME problem. Because the four curves in Figs. 2(A–D) are monotone, all the points are
Pareto-efficient, i.e., it is not possible to improve one objective (e.g., ∆) without worsening the
other one (e.g., φI ). We notice that past a certain value of ε (10 in the ReMF case, 103 in the
ReME case) ∆ and Gmax do not further decrease and Gmin and φI remain unchanged. We
choose as weights αp = 10 and αI = 1 for p = 1, while we choose αp = 103 and αI = 1 for
p = 2 (these are highlighted by dashed circles in Fig. 2). The reason for these choices (for both
values of p) is that these values yield φI ∼ 10 units, which is equal to two thirds of the
maximum amount of insulin that can be supplied (φUI ), and G
min ∼ 93mg/dL, which is far from
the hypoglycemic risk region.
In Fig. 2E, we plot a projection of the Pareto front in the ∆ and φI plane. Looking at this
plot, the trade-off between ∆ and φI is evident; if the total amount of insulin expenditure
increases, ∆ decreases and vice-versa. The ReMF and the ReME therapies can also be
compared in Fig. 2E. The ReMF Pareto front dominates the ReME one (both ∆ and φI are
lower on the blue curve (p = 1) compared to the magenta curve (p = 2)). This indicates that a
shot of insulin (the optimal solution of a ReMF problem is typically a pulsatile function)
performs slightly better in terms of ∆ than a therapy in which the drug is delivered over a longer
period of time while using less insulin.
Figure 3 shows the results of the optimal control problem for the selected values of αp and
αI . The blue and magenta curves are the optimal solutions of the ReMF and of the ReME
problem, respectively. The orange curve corresponds to the case that 10 U of insulin are injected
30 minutes before the time of the meal, i.e., , the standard therapy.
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Fig 2. Performance of the optimal control solution as a function of ε. Large (small) values of ε correspond to a
large (small) weight associated with the BGI index in the objective function, compared to the weight for insulin
expenditure. The first four plots show our metrics as functions of the objective function coefficients: A) ∆ vs. ε, B)
Gmin vs. ε, C) Gmax vs. ε, and D) φI vs. ε. E) We also project the Pareto front into the ∆ - φI plane. We see a
clear trade-off between ∆ and φI as we vary ε. By increasing ε we can decrease the values of ∆ and Gmax.
However, the values of ∆ and Gmax do not further decrease for ε larger than 10 for the ReMF problem (p = 1) and
the value of ∆ does not further decrease for ε larger than 103 for the ReME problem (p = 2). We choose ε = 10
for p = 1 and ε = 103 for p = 2, which are indicated by dashed circles in the figure, for the remaining simulations.
We observe that for p = 1 the optimal insulin infusion rate is pulsatile with a pulse appearing
at t ∼ 20 minutes, which is 40 minutes before the time of the meal. We obtained qualitatively
similar results for different choices of the model parameters, with the pulse typically appearing
at a time in the interval t ∈ [20, 30] minutes. It is noteworthy that the optimal solution is close to
the standard insulin based therapy for glucose regulation in diabetics. The optimal insulin
infusion rate is continuous when we solve the ReME problem, also shown in the inset of Fig. 3B.
Note that the ReMF and ReME therapies perform very similarly with respect to glucose as the
peak insulin infusion rate occurs at approximately the same time and the total amount of insulin
administered is nearly equal.
3.2 Insulin and Glucagon as Control Inputs
In the previous section we tuned the weights αp and αI inside the objective function (2). We
now consider the case that uG > 0 and we tune αG, the weight associated with the glucagon
expenditure in the objective function (2), by keeping αp = 10, αI = 1 for p = 1 and αp = 103,
αI = 1 for p = 2 , as previously determined.
In Fig. 4A, 4B and 4C, we plot the optimal ∆, Gmin and Gmax as functions of the parameter
αG, respectively. A large value of αG indicates that we are placing a large weight on the
expenditure of glucagon within the objective function (2), i.e., , the larger the value of αG, the
less glucagon we use. By looking at Fig. 4A, we observe that the values of ∆ decrease as αG
decreases, i.e., we can obtain lower (improved) values of ∆ if we allow for a larger expenditure
of glucagon. We note that past a certain value of αG (10−2 in the both the ReMF and ReME
problems) no further reduction in ∆ is observed. As in the previous case, the maximum glucose
level Gmax, shown in Fig. 4C, improves (decreases) when ∆ improves (decreases). Interestingly,
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different from the previous case, also the minimum glucose level Gmin (Fig. 4C) improves
(increases) with ∆ and Gmax: this is a consequence of the fact that we are using both insulin and
glucagon as control inputs, which enables us to avoid both hypoglycemia and hyperglycemia.
In Fig. 4D we plot the projection of the Pareto front in the (φI , φG) plane. By looking at the
figure, φI and φG appear to be positively correlated and related by an approximately linear
relation. While the timing of administration of insulin and glucagon is different, we see that
overall the more insulin is used in the optimal solution, the more glucagon is used as well. This
is because the two hormones have opposite effects in the regulation problem and thus they work
so as to balance each other. This is also consistent with the observation that with the dual drug
therapy (insulin and glucagon) it becomes possible to simultaneously improve ∆, Gmin, and
Gmax. From the data in Fig. 4D we derive the following approximate linear relationship
between φG and φI ,
φG(φI) = 0.1596φI − 1.5796 (11)
Obviously, glucagon should be used only when φG(φI) > 0.
Panel 4E shows a projection of the Pareto front on the (φG,∆) plane. We see again that the
ReMF front dominates the ReME one, i.e., a pulsatile therapy gives better results than a
continuous therapy in terms of ∆ and also uses lower amounts of the two drugs (smaller φG, and
thus smaller φI due to the positive correlation found in Fig. 4D).
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Fig 3. A) The time evolution of glucose G(t) (in mg/dL). The blue curve corresponds to the pulsatile optimal
insulin supply rate uI(t) (shown in B) obtained by solving the ReMF problem. The magenta curve corresponds to
the continuous optimal insulin supply rate uI(t) (shown in B) obtained by solving the ReME problem. The orange
curve is the time evolution of G(t) corresponding to the standard therapy (10 U of insulin injected 30 minutes
before the time of the meal). B) Time evolution of the optimal insulin infusion rates uI(t) (in U/min). Color code
is consistent with A. C) Cumulative insulin supply rI(t) (in U) as a function of t.
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vs. αG. D) φI vs. φG. E) ∆ vs. φG. We select αG = 10−2 for both of the REMF and REME problems, which are
indicated by dashed circles in the figure.
The Pareto front is monotonically decreasing in Fig. 4E which indicates a trade-off between
the total amount of drugs used and the achievable glucose control performance. We choose the
value of αG for which the ratio between the increase in ∆ and the decrease in φG is minimized,
i.e., αG = 10−2 for both ReMF and ReME problems, which are indicated by dashed circles in
the figure.
Figures 5A and 5B show the results of the optimal control problem for αp = 10, αI = 1 and
αG = 10
−2 when p = 1; and αp = 103, αI = 1 and αG = 10−2 when p = 2. In Fig. 5A we
plot the time evolution of glucose G(t) for the different optimal solutions. The blue curve
corresponds to the solution of the ReMF problem when only insulin is used (the blue curve in
Fig. 3A). The red and green curves correspond to the solution of the ReMF and the ReME
problems for the dual drug therapy. We observe that G(t) reaches the desired level Gd faster if
we use both insulin and glucagon as control inputs, compared to the case that only insulin is
used. We also see that in this case both Gmax decreases and Gmin increases. We therefore
conclude that the therapy with both insulin and glucagon performs better than the therapy with
only insulin, as the risks for both hypoglycemia and hyperglycemia are reduced and glucose
fluctuations are suppressed.
In Fig. 5B we plot the optimal insulin infusion rates and in Fig. 5C we plot the cumulative
insulin supply rI(t) as a function of time t. We observe that for the ReMF problem, the pulse in
insulin appears at t = 32 minutes in the case that both insulin and glucagon are used (28 minutes
before the meal), whereas the pulse appears at t = 20 minutes when only insulin is used. From
Fig. 5D, we see that, for the ReMF problem, the glucagon delivery function is pulsatile with a
main pulse appearing at t = 145 min (one hour and 25 minutes after the meal) and a secondary
pulse appearing at t = 203. The dual drug therapy shows a noticeable difference between the
ReMF solution and the ReME solution. As expected, the solutions of the ReME problem are
continuous. The glucose response to the ReME therapy is better than the glucose response to the
ReMF solution. Specifically, the green curve has smaller oscillations (in panel A) at the cost of
small increases in the total amounts of used insulin and glucagon (compare panels C and E)).
Based on the results in Fig. 5, we propose a possible ad-hoc dual drug therapy to be used as
an alternative to the standard therapy. Rather than administering insulin half an hour before the
February 28, 2019 11/29
0 50 100 150 200 250 300
90
110
130
150
A)
Time (t) (min)
G
lu
co
se
(m
g/
d
L
)
Optimal solution of the ReMF (p = 1) problem,
∆ = 105.17, φI = 10.07 U,
Gmin = 92.85 mg/dL, Gmax = 130.6490 mg/dL
Optimal solution of the ReMF (p = 1) problem;
Insulin and glucagon are control inputs;
∆ = 21.96 , φI = 12.43 U, φG = 0.37 mg,
Gmin = 99.0 mg/dL, Gmax = 123.0 mg/dL
Optimal solution of the ReME (p = 2) problem;
Insulin and glucagon are control inputs;
∆ = 14.66, φI = 13.29 U, φG = 0.53 mg,
Gmin = 100.43 mg/dL, Gmax = 120.15 mg/dL
0 50 100 150 200 250 300
0
5
10
15
B)
Time (t) (min)
In
su
li
n
in
fu
si
on
ra
te
(U
/m
in
)
0 50 100 150 200 250 300
0
5
10
15
C )
Time (t) (min)
C
u
m
u
la
ti
ve
In
su
li
n
r I
(t
)
(U
)
0 50 100 150 200 250 300
0
0.1
0.2
0.3
D)
Time (t) (min)
G
lu
ca
go
n
in
fu
si
on
ra
te
(m
g/
m
in
)
0 50 100 150 200 250 300
0
0.5
1
E )
Time (t) (min)
C
u
m
u
la
ti
ve
gl
u
ca
go
n
r G
(t
)
(m
g)
0 100 200 300
0
0.1
0.2
0 100 200 300
0
0.005
0.01
Fig 5. A) Time evolution of glucose G(t) (in mg/dL). The blue curve corresponds to uI(t) obtained by solving the
ReMF problem . The red curve corresponds to uI(t) and uG(t) obtained by solving the ReMF problem using the
dual drug therapy. The green curve corresponds to uI(t) and uG(t) obtained by solving the ReME problem using
the two-drug-therapy. B) Time evolution of the insulin infusion rate uI(t) (in mg/dL). Color code is consistent
with A. C) The cumulative insulin supply rI(t) as a function of time t. D) Time evolution of the glucagon infusion
rate uG(t) (in mg/dL). E) The cumulative glucose supply rG(t) as a function of time t.
meal (standard therapy), better glucose regulation can be achieved with a slightly larger insulin
injection half an hour before a meal followed by a glucagon injection one hour and thirty
minutes after a meal. The insulin injection of the ad-hoc dual drug therapy is 25% larger than
the one used in the standard therapy, which is consistent with the relation between φI for the
monotherapy ReMF optimal solution and the one used in the dual drug therapy.
In Fig. 6 we present a comparison between the glucose response to the standard insulin base
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proposed ad-hoc dual therapy (cyan curve).
therapy (orange curve) and the proposed ad-hoc dual therapy (cyan curve) for the case of a meal
with 70 grams of glucose (for the particular patient considered this corresponds to 10 units of
insulin half an hour before the meal) and the proposed ad-hoc dual drug therapy (which consists
of 12.43 units of insulin thirty minutes before the meal and 0.40 mg of glucagon one hour and
thirty minutes after the meal). We observe that the ad-hoc dual drug therapy performs better in
terms of all of the proposed measures (∆, Gmin, Gmax, φI and φG) as opposed to the standard
insulin based therapy.
3.3 Robustness Analysis
We now analyze the robustness of the optimal control therapies we have proposed with respect
to model parameter mismatches, which is a fundamental step for implementation of model based
control. We consider two different types of mismatches. The first type accounts for variability in
the patient’s behavior, in terms of both the time of the meal τD and the amount of glucose intake
D. The second type accounts for deviations in the parameter estimation, as well as the temporal
variability of the parameters that a patient may experience during the day [4].
3.3.1 Robustness Against Variability of the Meal Time and Glucose Intake
In this section we analyze the robustness of the optimal ReMF therapies (both monotherapy and
dual therapy) with respect to the two “control” parameters the patient has. The first one is the
variation in the meal time, (τ¯D − τD) (min), where τ¯D is the time of a meal and τD is the time of
a meal we assumed in order to compute the optimal therapies. The second one is the variation of
glucose in the meal, (D¯ −D), where D¯ is the glucose intake in a meal and D is the glucose
intake we assumed to compute the optimal therapies. We consider variations in the meal time τ¯D
in the interval [30, 90] min and variations of the glucose intake D¯ in the interval [40, 100] g.
The results of this study are illustrated in Fig. 7. Figure 7 provides a visual assessment of the
quality of the optimal therapies in terms of the three proposed measures ∆, Gmax and Gmin (the
over-bar stands for evaluation at the perturbed parameter values (τ¯D, D¯)). The color in Fig. 7
varies according to the control performance from green (good) to red (dangerous). In the upper
panels (A–C) we consider the optimal ReMF monotherapy, while in the lower panels (D-F) we
consider the optimal ReMF dual thearpy. Cross symbols indicate the application of the optimal
control therapies under ideal condition, i.e., when τ¯D = τD and D¯ = D. The black curves
labeled by 180, 90 and 70 in Figs. 7B, 7C, 7D, 7E are the curve level plots for G¯max = GU ,
G¯min = GL and G¯min = 70, respectively. The black curves labeled by 180 in Figs. 7B, and 7E,
are the curve level plots for G¯max = GU .
We see from Figs. 7A and 7D that the optimal therapies for the ReMF problem (using only
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insulin or both insulin and glucagon) are robust with respect to variations in the control
parameters: ∆¯ remains well bounded in most of the considered parameter space. In particular
we see from Figs. 7B and 7E that the proposed optimal therapies are robust against
hyperglicemic events: for example, even if D¯ exceeds D by 50% and τ¯D exceeds τD by 30
minutes, the patient will not enter the hyperglycemic regime (Gmax > 300). Figures 7C and 7F
reveal that the proposed therapies suffer from a certain lack of robustness with respect to
hypoglycemic events (Gmin < 70), the most dangerous ones. The dangerous cases are, however,
confined to extreme situations in which D¯ < 0.5D and τ¯D = τD + 30 minutes. Figures 7C and
7F show also that the optimal therapy for the ReMF problem with both insulin and glucagon is
more robust (larger green region and smaller yellow region) than the optimal therapy for ReMF
problem with only insulin (smaller green region and larger yellow region): thus the use of
glucagon alleviates the risk of severe, life-threatening hypoglycemia.
We obtain qualitatively similar results when performing the same analysis for the other
therapies we proposed (the ReME therapies and the ad-hoc dual drug therapy).
3.3.2 Robustness to Parameter Mismatches
We consider perturbation of the model parameters up to 20% of their nominal values,
Θ¯i = Θi(1 + ϕ), (12)
where ϕ is a random number from a normal distribution N (0, 0.0672), Θi is a nominal
parameter for a given patient with basal glucose level Gb and Θ¯i represents the associated
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Fig 7. Robustness of the optimal control solution against variations in the meal timing and the amount of glucose
in the meal. A)–C) show the results obtained for the ReNF problem (p = 1) with only insulin provided, D)-F)
ReMF (p = 1) problem with both insulin and glucagon provided. Cross symbols indicate the application of the
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control parameters space (τ¯D, D¯).
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perturbed parameter. We then apply the optimal insulin and glucagon dosing, calculated for the
unperturbed system, to 100 perturbed systems. This is analogous to testing the computed
optimal control therapy on a specific patient, but the patient’s parameters may vary due to
imperfect knowledge or due to the parameter variability throughout the day. The results of this
study are illustrated with a Control Variability Grid Analysis (CVGA), see Fig. 8. The CVGA
provides a simultaneous visual and numerical assessment of the overall performance of the
glycemic control strategies in terms of the achieved minimum/maximum glucose values in the
space of parameters mismatches. In Fig. 8, points in the light green region indicate accurate
blood glucose control while points in the dark green regions indicate the patient is not
immediately at risk of either hypoglycemia or hyperglycemia. Points in the top two
yellow/orange regions indicate an elevated risk of hyperglycemia and points in the the right two
yellow/orange regions indicate an elevated risk of hypoglycemia. Finally, points in the red
corner region indicate an elevated risk of both hyperglycemia and hypoglycemia. Each point
reported in the figure is a plot of Gmax vs. Gmin. Here, the black dots correspond to the glucose
response when a certain therapy is applied to a system with perturbed parameters. Cross
symbols indicate application of the optimal control therapies to the unperturbed systems.
For the of monotherapy (ReMF in Fig. 8A and ReME in Fig. 8B) we find that the control is
67% and 61% accurate, respectively. For the dual therapy case (ReMF in Fig. 8C and ReME in
Fig. 8D) we find the control is more accurate than for the case of monotherapy, 92% and 94%
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Fig 8. Robustness of the optimal control solution against parameter perturbations of the system and CVGA in the
Gmin, Gmax plane. The analysis is performed for A) ReMF (p = 1) problem with only insulin provided, B) ReME
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D) ReME (p = 2) problem with both insulin and glucagon provided, E) the standard therapy, and F) the proposed
ad-hoc dual drug therapy. Cross symbols indicate the application of the optimal control therapies to the
unperturbed systems.
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accurate, respectively. The least robust control is obtained with the standard therapy (shown in
Fig. 8E), attaining only 37% accuracy. Note that the optimal dual drug therapies (Figs. 8C and
8D) are not only more robust than the optimal insulin therapies (Figs. 8A and 8B), but also than
the standard therapy (8E). We also see that the ad hoc therapy (8E) is more robust than the
standard therapy (8E).
4 Discussion
In this paper we have used the Glucose-Insulin-Glucagon mathematical model proposed
in [2–4], which describes how the body responds to exogenously supplied insulin and glucagon
in patients affected by Type I diabetes and designed an optimal dosing schedule of either insulin
or insulin and glucagon together to regulate the blood glucose index (BGI), while limiting the
total amount of insulin and glucagon administered. The numerical optimal control software
PSOPT has been used to solve this optimal control problem. While the numerical solution
requires knowledge of the set of model parameters, which are patient specific, the solutions we
obtain provide insight into the best possible glucose regulation with insulin or with insulin and
glucagon together. Our approach is in agreement with the results of references [60–62], in which
simplified models are used to analytically establish general theoretical properties and control
limitations for the glucose regulation problem.
Two distinct regulation problems have been considered: the minimum fuel problem (ReMF)
which yields pulsatile (shot-like) type solutions and the minimum energy problem (ReME)
which yields longer periods of time over which insulin is administered but with smaller delivery
rates. This has allowed us to compare standard therapies which typically consist in shots of
insulin with therapies in which insulin is delivered continuously. In [63, 64] it has been proven
that the optimal control is pulsatile when the aim of the control is to minimize the variation in
the maximum and minimum output response, the system is positive (like the one we are
considering) and the disturbance (the meal, in our case) is pulsatile. Our work indicates that
pulsatile control is still a good choice when more complex objective functions are chosen.
Moreover, a pulsatile control appears to be optimal for alternative more realistic models of the
meal (for example, a meal that is consumed over a window of 15 minutes). We also see that a
continuous drug delivery can achieve better results in the case of the dual therapy, thus pointing
out the importance of developing a commercial pump able to deliver both insulin and glucagon.
For both the ReMF and ReME problems, we compute the optimal drug dosing schedules
when only insulin is available and when both insulin and glucagon are available. The solution of
the insulin only ReMF problem, astoundingly, is nearly equal to the standard method of insulin
based glucose regulation. Similarly, the solution of the ReMF problem when insulin and
glucagon are used is also pulsatile, except that the amount of insulin administered is larger and
the administration time is closer to the time of the meal, while the glucagon is mostly delivered
in a shot about an hour and thirty minutes after the meal.
The solution for the ReME problem when insulin only is available as well as when both
insulin and glucagon are available is different from the ReMF solution in that, rather than being
pulsatile, insulin and possibly glucagon are delivered at a slower rate over longer periods of time.
Nonetheless, the total amount of insulin and possibly glucagon is about the same, and the peak
of the longer delivery time occurs approximately at the same time of the shot according to the
solution of the ReMF problem. The obtained glucose profiles for the optimal ReMF and ReME
problem solutions do not differ too much from each other: taken together, these results indicate
that the amounts of insulin and glucagon, and the peak times of delivery, are the most important
factors to determine when computing the optimal solutions.
Based on the above results, we have proposed the following ad hoc therapy when insulin and
glucagon are used in combination: Administer a shot of insulin (with 5% more insulin than the
amount required by the standard therapy based on the planned meal) 30 minutes before eating.
Administer a shot of glucagon of an amount specified by Eq. (11) one hour and thirty minutes
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after completing the meal. This therapy must be used with caution as the amount of insulin
injected can lead to hypoglycemia if the shot of glucagon is not administered as well.
All optimal dosing schedules we computed were tested for robustness with respect to
variations in the meal timing and size and with respect to variability of the parameters. The
therapies we proposed typically maintain the patient in the healthy region even under variable
conditions and patient behavior. Note, however, that the proposed therapies are open-loop (the
drug schedule is computed only from the condition of the patient at the initial time), thus cannot
compensate for unexpected behavior that can arise due to modeling simplifications (e.g., we do
not consider how physical activity influences the blood glucose production and
consumption [65, 66]), measurement noise or bias. A step towards the real application of our
methodology is a real-time closed-loop strategy; this is possible, since the typical time needed to
compute an optimal solution on a standard laptop (i7-8550U CPU with 16GB RAM) is around 2
minutes. Another main limitation of our study is that real life constraints and long term
physiological effects may make a therapy based on exogenous administration of both insulin and
glucagon impractical.
Our optimal control strategies require knowledge of the meal time and meal glucose amount.
This is somewhat undesirable, as recent advances in diabetes therapy have moved towards
devices that do not require the user to provide information about the meals. Our results
emphasize the importance of knowing when the meals will occur, and that new dosing schedules
would benefit from some knowledge about the meals. This seems to indicate that it would be
beneficial to provide the pump with the ability to interpret the patient’s behavior.
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Supplementary Information
S1 GIGMModel and Parameters
S1.1 Overview of GIGMModel with Type I Diabetics
We consider the model in [3, 4] which is a system of nonlinear differential equations (ODEs). In
all equations, t is the physical time (in min), all subscripts b denotes basal state, and all of the
parameters are given in the table S1. The system of nonlinear differential equations are given
below:
Glucose Subsystem:
G˙p(t) = EGP (t) +Ra(t)− Uii − E(t)− k1Gp(t) + k2Gt(t), Gp(0) = Gpb (S1a)
G˙t(t) = −Uid(t) + k1Gp(t)− k2Gt(t), Gt(0) = Gtb (S1b)
G(t) =
Gp
VG
, G(0) = Gb (S1c)
Here Gp (in mg/kg) is the mass of plasma glucose; Gt (in mg/kg) is the mass of tissue glucose;
G (in mg/dL) is plasma glucose concentration and Vg (in dL/kg) is the distribution volume of
glucose; EGP is the endogenous glucose production (in mg/kg/min); Ra (in mg/kg/min) is the
rate of glucose appearance in plasma; Uii (in mg/kg/min) and Uid (in mg/kg/min) are
insulin-independent and insulin-dependent glucose utilizations, respectively. Also k1 and k2 are
the parameters.
Insulin Subsystem:
I˙p(t) = −(m2 +m4)Ip(t) +m1Il(t) +Ria(t), Ip(0) = Ipb (S2a)
I˙l(t) = −(m1 +m3)Il(t) +m2Ip(t), Il(0) = Ilb (S2b)
I(t) =
Ip(t)
VI
, I(0) = Ib (S2c)
Here Il (in pmol/kg) is the mass of liver insulin; Ip (in pmol/kg) is the mass of tissue insulin; I
(in pmol/L) is the plasma insulin concentration; VI (in L/kg) is the distribution volume of
insulin; Ria (in pmol/kg/min ) is the rate of appearance of insulin in plasma; m1, m2, m3 and
m4 are the parameters.
Glucose rate of appearance:
Qsto(t) = Qsto1(t) +Qsto2(t), Gsto(0) = 0 (S3a)
Q˙sto1(t) = −kgriQsto1(t) +Dδ(t− τD), Qsto1(0) = 0 (S3b)
Q˙sto2(t) = −kempt(Qsto)(t)Qsto2(t) + kgriQsto1(t), Qsto2(0) = 0 (S3c)
Q˙gut(t) = −kabsQgut(t) + kemptQsto(t)Qsto2(t), Qgut(0) = 0 (S3d)
Ra(t) =
f.kabs.Qgut(t)
BW
, Ra(0) = 0 (S3e)
kempt(Qsto) = kmin +
kmax − kmin
2
. (S3f)
{tanh[α(Qsto − b.D)]− tanh[β(Qsto − c.D)] + 2} (S3g)
Here Qsto (in mg) is the amount of glucose in the stomach, Qsto1 (in mg) is the amount of
liquid glucose in the stomach, Qsto2 (in mg) is the amount of solid glucose in the stomach, Qgut
(in mg) is the glucose mass in the intestine; D (in mg) is the amount of ingested glucose at time
τD; BW (in kg) is body weight; kempt is the rate constant of the gastric emptying; Kgri, kabs,
kmax, kmin, f , α, β are the parameters.
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Endogenous glucose production:
EGP (t) = kp1 − kp2Gp(t)− kp3XL(t) + ξXH(t), EGP (0) = EGPb (S4a)
I˙ ′(t) = −ki [I ′(t)− I(t)] , I ′(0) = Ib (S4b)
X˙L(t) = −ki
[
XL(t)− I ′(t)] , XL(0) = Ib (S4c)
X˙H(t) = −kHXH(t) + kH ×max [H(t)−Hb, 0] , XH(0) = 0 (S4d)
Here XL (in ) is delayed insulin action on EGP ; XH is delayed glucagon action on EGP ; I ′
is delayed insulin in compartment 1; kp1, kp2, kp3, ξ, ki, kH are the parameters.
Glucose utilization:
Uii(t) = Fcns (S5a)
Uid(t) =
[Vm0 + Vmx.X(t)]Gt(t)
Km0 +Gt(t)
(S5b)
X˙(t) = −p2UX(t) + p2U [I(t)− Ib], X(0) = 0 (S5c)
Here Uii (in mg/kg/min) and Uid (in mg/kg/min) are insulin-independent and insulin-dependent
glucose utilization; X (in pmol/L) is insulin in interstitial fluid; Fcns, Vm0, Km0, p2U are the
parameters.
Renal excretion:
E(t) =
{
ke1[Gp(t)− ke2] if Gp(t) > ke2
0 if Gp(t) ≤ ke2
(S6)
Here E(t) (in mg/kg/min) is the glucose renal exertion; ke1 is the parameter.
Glucagon kinetics and secretion:
H˙(t) = −nH(t) + SRH(t) +RaH(t), H(0) = Hb
(S7a)
SRH(t) = SR
s
H(t) + SR
d
H(t), (S7b)
S˙RsH(t) = −ρ
[
SRsH(t)−max
(
σ[Gth −G(t)]
max(I(t)− Ith, 0) + 1 + SR
b
H , 0
)]
, SRsH(0) = nHb
(S7c)
SRdH(t) = δmax
(
−dG(t)
dt
, 0
)
(S7d)
Here H (in ng/L) is the concentration of plasma glucagon; SRH (in ng/L/min) is the glucagon
secretion; RaH (in ng/L/min) is the rate of appearance of glucagon in plasma; SRsH (in
ng/L/min) and SRdH (in ng/L/min) is the static and dynamic components of glucagon,
respectively; n, ρ, Ith, δ are the parameters.
Subcutaneous insulin kinetics:
Ria(t) = ka1Isc1(t) + ka2Isc2(t) (S8a)
I˙sc1(t) = −(kd + ka1)Isc1(t) + IIR(t), Isc1(0) = Isc1ss (S8b)
I˙sc2(t) = kd.Isc1(t)− ka2Isc2(t), Isc2(0) = Isc2ss (S8c)
IIR(t) = IIRb +
uI(t)
BW
(S8d)
Here Ria (in pmol/kg/min) is the rate of appearance of insulin in plasma; Isc1 (in pmol/kg) is
the amount of nonmonomeric insulin in the subcutaneous space; Isc2 is the amount of
February 28, 2019 24/29
monomeric insulin in the subcutaneous space; IIR(t) is the insulin infusion rate where IIRb is
the basal infusion rate (in pmol/kg/min) from body and uI (in pmol/min) is the external insulin
infusion rate; ka1, ka2, kd are the parameters. As the exogenous insulin infusion rate appears in
the above equation in pmol/kg/min, we divide uI by the body weight BW in the equation. Note
that here the uI is in pmol/min. To convert the unit of insulin infusion rate uI from U/min to
pmol/min, we multiply uI by 6944.4, that is the unit conversion is 1 U/min = 6944.4 pmol/min.
Subcutaneous glucagon kinetics:
H˙sc1(t) = −(kh1 + kh2)Hsc1(t) +GIR(t), Hsc1(0) = Hsc1ss (S9a)
H˙sc2(t) = kh1Hsc1(t)− kh3Hsc2(t), Hsc2(0) = Hsc2ss (S9b)
RaH(t) = kh3Hsc2(t) (S9c)
GIR(t) = GIRb +
uG(t)
BV
(S9d)
Here Hsc1 (in ng/L) and Hsc2 (in ng/L) are the glucagon concentration in the subcutaneous
space; IGR is the glucagon infusion rate where GIRb is the basal glucagon infusion rate (in
ng/L/min) from the body and uI is the external glucagon infusion rate (in ng/min);kh1, kh2, kh3
are the parameters. As the exogenous glucagon infusion rate appears in the above equation in
ng/L/min, we divide uG by the body volume BV in the equation. Note that here the uG is in
ng/min. To convert the unit of glucagon infusion rate from mg/min to ng/min, we multiply uG
by 106, that is the unit conversion is 1 mg/min = 106 ng/min.
We write the ODEs in Eqs. (S1)-(S9) in the form x˙(t) = f(x(t),u(t),ΘGb) where x ∈ R17
and t is the physical time (in min). The variable x1 represents Gp, the mass of glucose in
plasma; the variable x2 represents Gt, the mass of glucose in tissue; the variable x3 represents
the mass of liver insulin Il; the variable x4 represents the mass of plasma insulin Ip; the variable
x5 represents the amount of delayed insulin I ′ in compartment 1; the variable x6 represents the
amount of delayed insulin XL action on EGP ; the variable x7 represents the amount of solid
glucose Qsto1 in the stomach; the variable x8 represents the amount of liquid glucose Qsto2 in
the stomach; the variable x9 represents the glucose mass Qgut in the intestine; the variable x10
represents the amount of interstitial fluid X; the variable x11 represents the amount of static
glucagon SRsH ; the variable x12 represents the amount of plasma glucagon H; the variable x13
represents the amount of delayed glucagon XH action on EGP ; the variable x14 represents the
amount of nonmonomeric insulin Isc1; in the subcutaneous space; the variable x15 represents
the amount of monomeric insulin Isc2 in the subcutaneous space; the variable x16 represents the
amount of subcutaneous glucagon Hsc1 in the subcutaneous space; the variable x17 represents
the amount of subcutaneous glucagon Hsc2 in the subcutaneous space. Also
u(t) = [uI(t) uG(t)]T , where uI is the external insulin and uG is the external glucagon. We
define ΘGb as the set of parameters for which the basal glucose level is Gb.
S1.2 Parameters
There are a total of 46 parameters in Eqs. (S1)-(S9). The parameters are not given in [3]. We set
all the parameters for ‘Glucose subsystem’, ‘Insulin subsystem’, ‘Glucose rate of appearance’,
‘Endogenous glucose production’, ‘Glucose utilization’, ‘Glucose utilization’, ‘Renal excretion’,
‘Subcutaneous insulin kinetics’ from the references [1, 2], except kp1, Vm0 and HEb. According
to [2], the parameters are chosen to satisfy the steady-state constraints in type I diabetes. The
parameters kp1 and Vm0 are set so that the steady state solutions provide the basal Glucose level
Gb and EGPb = 2.4. In Type I diabetes, the endogenous glucose production is high [2], so we
choose EGPb = 2.4 mg/kg/min. We set IIRb = 0 and GIRb = 0 as the model we consider is
for Type I diabetes. The commercial version of the UVA/Pavoda simulator [68] allows
computing blood glucose responses to supplied dosages of insulin for some patients, but does
not provide all of the parameters. We tune the parameter HEb so that the blood glucose
response to insulin of the patient we consider in this paper is qualitatively similar to the blood
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glucose response to insulin of a patient from the software [68] (adultaverage.mat). All of the
parameters we use are listed in the Table S1 for reproducibility of the results. Our
implementation of the model [3] has been published in GitHub [69].
The equations for kp1 and Vm0 are given below:
kp1 = EGPb + kp2Gpb + kp3Ib (S10a)
Vm0 =
(EGPb − Fcns)(Km0 +Gtb)
Gtb
(S10b)
The basal steady states are given below:
Gpb = Gb.Vg (S11a)
Gtb =
Fcns − EGPb + k1Gpb
k2
(S11b)
Ilb = Ipb.
m2
m1 +m3
(S11c)
Ipb =
IIRb
m2 +m4 − m1m2m1+m3
(S11d)
Isc1ss =
IIRb
kd + ka1
(S11e)
Isc2ss =
kd
ka2
Isc1ss (S11f)
SRsHb = nHb (S11g)
Hsc1ss =
GIRb
kh1 + kh2
(S11h)
Hsc2ss =
kh1
kh3
Hsc1ss (S11i)
Here, the basal values Gb (in mg/dL), IIRb (in pmol/kg/min) and GIRb (in ng/L/min) are
settable by the user.
S2 Network Representation of the GIGMModel
In this section we construct a graph representation of the GIGM model. A graph G(V, E),
consists of a set V = {xi}, i = 1, . . . , n of nodes and a set E of directed edges, where each edge
is identified by an ordered pair {xi, xj} of nodes xi, xj ∈ V .
Complex networks typically consist of two parts; a set of nodes with their interconnections
which represent the topology of the network, and the dynamics which describes the time
evolution of the network nodes. The prescribed dynamics of the nodes can be linear or
non-linear. We can construct a complex network from a dynamical system, simply by
considering a state variable as a node and by drawing a directed edge from a node xi to another
node xj if xi appears in the time derivative of xj . We call driver nodes, the nodes which directly
connect to the external inputs. We call target nodes, the nodes which have prescribed state that
must be satisfied at the final time [50].
A network representation of the GIGM model is shown in Fig. S1. Each one of the state
variable xi, i = 1, · · · , 17, in Eqs. (S1)-(S9) is associated with a node (shown as a green circle
in the figure). A directed edge (shown as a black arrow in the figure) is drawn from node xi to
node xj , if the state xi appears in the time derivative of the state xj . For instance, as Gt appears
on the right hand side of Eq. (S1a), there exists an edge from node Gt to node Gp. In the model
in Eqs. (S1)-(S9), uI and uG are the external inputs acting on the nodes Isc1 and Hsc1,
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Table S1. Average parameters
Parameter Type I Value Unit
BW 78 [1] Kg
BV 78 [1] L
Vg 1.49 [1] dL/kg
k1 0.065 [1, 2] min−1
k2 0.079 [1, 2] min−1
VI 0.04 [1] L/kg
m1 0.379 [1] min−1
m2 0.673 [1] min−1
m4 0.269 [1] min−1
m5 0.0526 [1] min.kg/pmol
m6 0.8118 [1] dimensionless
HEb 0.112 [1] dimensionless
kp1 change Eq. (S10) mg/kg/min
kp2 0.0021 [1, 2] min−1
kp3 0.009 [1, 2] mg/kg/min per pmol/L
kp4 0.0786 [1] mg/kg/min per pmol/L
ki 0.0066 [1] min−1
kmax 0.0465 [1] min−1
kmin 0.0076 [1] min−1
kabs 0.023 [1] min−1
kgri 0.0465 [1] min−1
f 0.9 [1] dimensionless
a 0.00016 [1] mg−1
b 0.68 [1] dimensionless
c 0.00023 [1] mg−1
d 0.009 [1] dimensionless
Fcns 1 [1] mg/kg/min
Vm0 changes (Eq. (S10) mg/kg/min
Vmx 0.034 [1] mg/kg/min per pmol/L
Km0 4661.21 mg/kg
P2u 0.084 [1] min−1
ke1 0.0007 [1] min−1
ke2 269 [1] mg/kg
kd 0.0164 [2] min−1
ka1 0.0018 [2] min−1
ka2 0.0182 [2] min−1
δ 0.682 [3] (ng/L per mg/dL)
σ 1.093 [3] min−1
n 0.15 [3] min−1
ζ 0.009 [3] (mg/kg/min per ng/L)
ρ 0.57 [3] (ng/L/min per mg/dL)
kH 0.16 [3] min−1
Ith Ib [3] (pmol/L)
Gth Gb [3] mg/dL
kh1 0.0164 [3] min−1
kh2 0.0018 [3] min−1
kh3 0.0182 [3] min−1
Average parameters.
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Table S2. Basal values
Basal Type I Value Unit
XHb 0 [67] pmol/L
EGPb 2.4 [2] mg/kg/min
Hb 93 [67] ng/L
IIRb 0 [2] pmol/kg/min
Basal values.
respectively. Thus the set of drivers node D = {Isc1, Hsc1}. In this model as the plasma
glucose Gp is the only variable we are trying to affect through the control action, thus the set of
target nodes T = {Gp}. In the figure, the driver nodes are colored cyan and the target node are
colored magenta. As can be seen, the effect of the control inputs on the target node is mediated
by the network structure, thus this particular structure plays an important role in our ability to
control the network output. While the effect of the network topology has been investigated in the
case of linear network dynamics, see e.g. [70–81], the case of nonlinear networks has so far
received only limited attention [82–85]. Reference [42] and this paper investigate this problem
in the context of two applications of interest to the medical field.
S3 Continuous Approximation of Non-differential Function
in ODEs
The optimization algorithms implemented in PSOPT require the derivatives of the function
f(x(t),u(t),ΘGb) exists. We notice that there are discontinuities in Eqs. (S1)-(S9).
Glucose Subsystem
Insulin Subsystem
Endogenous Glucose Production
Glucose Utilization
Glucagon Subsystem
Subcutaneous Insulin Subcutaneous Glucagon
Gp
Gt
IlIp
I ′
XL
Qsto1
Qsto2Qgut
X
SRsH
H
XH
Isc1
Isc2
Hsc1
Hsc2
uI uG
G
V = {Gp, Gt, Il, Ip, I ′, XL, Qsto1, Qsto2, Qgut, X, SRsH , H,XH , Isc1, Isc2, Hsc1, Hsc2}
D = {Isc1, Hsc1}
T = {Gp}
Fig S1. Network representation of the GIGM model.
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The smooth approximation of the Renal exertion function E(t) in Eq. (S6) by using a Heaviside
function is,
E(t) = ke1(Gp(t)− ke2)×H(Gp(t), ke2, k), (S12)
where,
H(Gp(t), ke2, k) = 1
1 + e−k(Gp−ke2)
, k ∈ Z. (S13)
Here a larger k corresponds to a sharper transition around Gp(t) = ke2.
We define a continuous approximation of the Dirac delta function δ(t− τD) in Eq. (S3c),
δ(t− τD) = d
dt
H(t, τD, k), (S14)
whereH(t, τD, k) = 11+e−k(t−τD) , k ∈ Z. Here a larger k corresponds to a sharper transition at
t = τD.
We also define continuous approximation of the max(.) function, e.g. in Eq. (S4d), as
max(H(t)−Hb, 0) = (H(t)−Hb)×H(H(t), Hb, k), (S15)
whereH(H(t), Hb, k) = 11+e−k(H−Hb) , k ∈ Z. Here a larger k corresponds to a sharper
transition at H(t) = Hb. In all our approximation we set k = 4.
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